Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTOR Citius Oncology	$1.53 -4.4%	$2.05	$0.55 ▼ $6.19	$114.48M	3.06	1.30 million shs	573,376 shs
TKNO Alpha Teknova	$4.27 -2.1%	$5.58	$1.90 ▼ $10.37	$233M	0.33	378,570 shs	254,528 shs
TRDA Entrada Therapeutics	$6.26 -1.9%	$7.47	$6.23 ▼ $21.79	$242.14M	-0.11	134,454 shs	118,687 shs
VNRX VolitionRx	$0.68 -0.2%	$0.63	$0.40 ▼ $0.94	$70.19M	1.2	207,835 shs	158,216 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTOR Citius Oncology	+1.91%	-50.77%	+10.34%	+138.13%	+159,999,900.00%
TKNO Alpha Teknova	+1.16%	-15.99%	-19.11%	-24.31%	+127.08%
TRDA Entrada Therapeutics	0.00%	-5.62%	-11.51%	-21.53%	-62.73%
VNRX VolitionRx	-3.39%	-0.54%	+3.73%	+38.02%	+3.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTOR Citius Oncology	1.637 of 5 stars	3.0	0.0	3.0	1.7	0.0
TKNO Alpha Teknova	2.184 of 5 stars	3.5	1.0	2.7	1.7	0.6
TRDA Entrada Therapeutics	3.3418 of 5 stars	3.6	1.0	3.0	2.5	1.9
VNRX VolitionRx	2.1339 of 5 stars	3.5	0.0	2.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTOR Citius Oncology	2.00	Hold	$3.00	96.08% Upside
TKNO Alpha Teknova	3.00	Buy	$12.00	181.03% Upside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	310.01% Upside
VNRX VolitionRx	3.00	Buy	$3.50	418.52% Upside

Current Analyst Ratings Breakdown

Latest VNRX, TRDA, CTOR, and TKNO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/10/2025	VNRX VolitionRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
5/23/2025	CTOR Citius Oncology	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/23/2025	CTOR Citius Oncology	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/20/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/30/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.64 per share	N/A
TKNO Alpha Teknova	$37.74M	6.05	N/A	N/A	$1.55 per share	2.75
TRDA Entrada Therapeutics	$210.78M	1.13	$1.56 per share	4.02	$11.46 per share	0.55
VNRX VolitionRx	$1.31M	53.65	N/A	N/A	($0.11) per share	-6.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTOR Citius Oncology	N/A	N/A	0.00	∞	N/A	N/A	-53.88%	-18.86%	N/A
TKNO Alpha Teknova	-$26.75M	-$0.48	N/A	N/A	N/A	-60.90%	-28.48%	-19.73%	8/12/2025 (Estimated)
TRDA Entrada Therapeutics	$65.63M	$0.81	7.73	N/A	N/A	14.39%	5.84%	4.61%	8/12/2025 (Estimated)
VNRX VolitionRx	-$35.32M	-$0.27	N/A	∞	N/A	-2,321.14%	N/A	-163.39%	N/A

Latest VNRX, TRDA, CTOR, and TKNO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	TRDA Entrada Therapeutics	-$0.86	N/A	N/A	N/A	$8.17 million	N/A
5/14/2025	Q2 2025	CTOR Citius Oncology	-$0.09	-$0.11	-$0.02	-$0.11	$5.74 million	N/A
5/8/2025	Q1 2025	TKNO Alpha Teknova	-$0.11	-$0.09	+$0.02	-$0.09	$9.41 million	$9.60 million
5/8/2025	Q1 2025	TRDA Entrada Therapeutics	-$0.78	-$0.42	+$0.36	-$0.42	$10.98 million	$8.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
TKNO Alpha Teknova	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTOR Citius Oncology	0.11	0.36	0.05
TKNO Alpha Teknova	0.17	5.64	4.71
TRDA Entrada Therapeutics	N/A	21.88	21.88
VNRX VolitionRx	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTOR Citius Oncology	70.52%
TKNO Alpha Teknova	13.81%
TRDA Entrada Therapeutics	86.39%
VNRX VolitionRx	8.09%

Insider Ownership

Company	Insider Ownership
CTOR Citius Oncology	4.57%
TKNO Alpha Teknova	12.50%
TRDA Entrada Therapeutics	8.11%
VNRX VolitionRx	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTOR Citius Oncology	N/A	71.55 million	68.28 million	N/A
TKNO Alpha Teknova	240	53.44 million	46.76 million	Not Optionable
TRDA Entrada Therapeutics	110	37.95 million	34.88 million	Optionable
VNRX VolitionRx	80	103.98 million	80.80 million	Optionable

VNRX, TRDA, CTOR, and TKNO Headlines

Recent News About These Companies

VolitionRx (NYSE:VNRX) Given "Buy" Rating at D. Boral Capital

July 17 at 9:07 AM | marketbeat.com

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

July 16 at 8:00 AM | prnewswire.com

VolitionRx (NYSE:VNRX) Earns Buy Rating from D. Boral Capital

July 12, 2025 | americanbankingnews.com

VolitionRx Limited (VNRX) - Yahoo Finance

July 11, 2025 | nz.finance.yahoo.com

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

July 8, 2025 | prnewswire.com

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

June 12, 2025 | prnewswire.com

Jones Trading Initiates Coverage of VolitionRx (VNRX) with Buy Recommendation

June 11, 2025 | msn.com

VolitionRx director Guy Innes buys $10,772 in common stock

June 5, 2025 | investing.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 20,000 Shares of Stock

June 5, 2025 | insidertrades.com

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

June 4, 2025 | prnewswire.com

VolitionRX shares hold as Benchmark maintains rating

May 21, 2025 | uk.investing.com

VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript

May 20, 2025 | msn.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Insider Acquires 50,000 Shares of Stock

May 20, 2025 | insidertrades.com

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 19, 2025 | prnewswire.com

VolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advances

May 16, 2025 | msn.com

VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript

May 16, 2025 | seekingalpha.com

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 15, 2025 | prnewswire.com

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 12, 2025 | prnewswire.com

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

May 7, 2025 | prnewswire.com

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

April 29, 2025 | prnewswire.com

VolitionRx enters new sales agreement, terminates old one

April 24, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Don’t Miss These 2 Small Quantum Stocks Poised to Pop
By Gabriel Osorio-Mazilli | June 24, 2025
View Don’t Miss These 2 Small Quantum Stocks Poised to Pop
Top 5 Stocks for July: Momentum-Driven Picks to Watch Now
By Thomas Hughes | June 30, 2025
View Top 5 Stocks for July: Momentum-Driven Picks to Watch Now
Joby vs. Archer: Which eVTOL Stock Is Better for Your Portfolio?
By Jeffrey Neal Johnson | July 14, 2025
View Joby vs. Archer: Which eVTOL Stock Is Better for Your Portfolio?
ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
By Gabriel Osorio-Mazilli | June 25, 2025
View ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside

VNRX, TRDA, CTOR, and TKNO Company Descriptions

Citius Oncology NASDAQ:CTOR

$1.53 -0.07 (-4.38%)

Closing price 04:00 PM Eastern

Extended Trading

$1.54 +0.00 (+0.33%)

As of 07:50 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Alpha Teknova NASDAQ:TKNO

$4.27 -0.09 (-2.06%)

Closing price 04:00 PM Eastern

Extended Trading

$4.43 +0.17 (+3.86%)

As of 04:49 PM Eastern

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

Entrada Therapeutics NASDAQ:TRDA

$6.26 -0.12 (-1.88%)

Closing price 04:00 PM Eastern

Extended Trading

$6.27 +0.01 (+0.16%)

As of 04:04 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

VolitionRx NYSE:VNRX

$0.68 0.00 (-0.19%)

Closing price 04:00 PM Eastern

Extended Trading

$0.68 +0.00 (+0.44%)

As of 04:15 PM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time